Numinus Wellness (TSX: NUMI) has received a major vote of confidence, announcing last night that it will be conducting a bought deal financing led by a VC firm, and will see participation from MAPS, a non-profit organization focused on research and education within the psychedelics space of mental health.
The venture capital firm leading the funding round is Integrated V.C., a firm that is focused on investing within the health and well being space. PitchBook suggests that the firm has conducted 15 different investments since its founding in 2021, two of which it has exited from.
“In light of the global renaissance in psychedelic drug development research, MAPS is enthused to support Numinus with their clinical work and the crucial training of therapists, including experiential training where therapists volunteer to receive psychedelics themselves in a therapeutic setting as part of a clinical trial. For more than half a century, therapists have expressed a desire to have the opportunity for their own psychedelic experiences as part of their training to feel better prepared to use these medicines to treat their patients. Given the potential demand for novel psychedelic-assisted therapy treatments, there will be a critical need for trained professionals to administer care. We see Numinus as playing a critical role in ensuring that therapists have the option to volunteer for experiential training to become fully trained on the latest medicines and their therapeutic methodologies,” commented Rock Doblin, Founder and President of MAPS.
Sponsored · Selkirk Copper Mines
While Integrated is said to be the lead order behind the offering, it is unclear how much they have committed to the financing. Similar data was also not provided for MAPS investment.
READ: Numinus Wellness Sells Off Shares In Alto Neuroscience Ahead Of IPO
The funding round overall is to amount to $6.0 million and is to be conducted at $0.12 per unit. Each unit is set to contain one common share and one common share purchase warrant. Warrants are valid for a period of two years and contain an exercise price of $0.18 per each.
The financing is being conducted on a bought deal basis, with Eight Capital leading a syndicate of underwriters.
Numinus Wellness last traded at $0.14 on the TSX.
Information for this briefing was found via Numinus Wellness. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
